# Tesamorelin Effects on Liver Fat and Histology in HIV

> **NCT02196831** · NA · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 61 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV)
- Nonalcoholic Fatty Liver Disease (NAFLD)
- Nonalcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** tesamorelin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02196831
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-01
- **Primary completion:** 2019-01-16
- **Final completion:** 2019-07-24
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2020-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02196831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02196831, "Tesamorelin Effects on Liver Fat and Histology in HIV". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02196831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*